Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of SHR-4298 injection in malignant solid tumors
CTR20254117Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4298 in Non-hematologic malignancy, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Dec 2025; status: active.
02
Drugs
SHR-4298
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20254117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254117.